Immunotherapy for Infectious Diseases

248 Dornburg and Pomerantz
6. Baltimore D. Intracellular immunization. Nature 1988; 235:395–396.
7. Caputo A, Grossi MP, Rossi C, et al. The tat gene and protein of the human immunodeficiency
virus type 1. N Microbiol 1995; 18:87–110.
8. Lisziewicz J. Tar decoys and trans-dominant gag mutant for HIV-1 gene therapy. Antibiot
Chemother 1996; 48:192–197.
9. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56:203–209.
10. Marasco WA. Intrabodies: turning the humoral immune system outside in for intracellular
immunization. Gene Ther 1997; 4:11–15.
11. Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious
diseases. Annu Rev Microbiol 1997; 51:257–283.
12. Earnshaw DJ, Gait MJ. Progress toward the structure and therapeutic use of the hairpin
ribozyme. Antisense Nucleic Acid Drug Dev 1997; 7:403–411.
13. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for
gene therapy. Prog Nucleic Acid Res Mol Biol 1998; 58:1–39.
14. James W. The use of ribozymes in gene therapy approaches to AIDS. Recent Results Cancer
Res 1998; 144:139–146.
15. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Therapeutic applications of
ribozymes. Pharmacol Ther 1995; 68:247–267.
16. Macpherson JL, Ely JA, Sun LQ, Symonds GP. Ribozymes in gene therapy of HIV-1. Front
Biosci 1999; 4:D497–D505.
17. Rossi JJ. Therapeutic applications of catalytic antisense rnas (ribozymes). Ciba Found
Symp 1997; 209:195–204.
18. Sun LQ, Ely JA, Gerlach W, Symonds G. Anti-HIV ribozymes. Mol Biotechnol 1997; 7:241–251.
19. Dornburg R. Reticuloendotheliosis viruses and derived vectors. Gene Ther 1995; 2:301–310.
20. Gunzburg WH, Salmons B. Development of retroviral vectors as safe, targeted gene delivery
systems [review]. J Mol Med 1996; 74:171–182.
21. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1:5–14.
22. Mitani K, Caskey CT. Delivering therapeutic genes—matching approach and application.
Trends Biotechnol 1993; 11:162–166.
23. Turchetto L, Benati C, Mattei S, et al. An approach to HIV gene therapy by transduction
of multifunctional retroviral vectors in primary human t lymphocytes. J Biol Regul Homeost
Agents 1997; 11:79–81.
24. Warner JF, Jolly D, Mento S, Galpin J, Haubrich R, Merritt J. Retroviral vectors for HIV
immunotherapy. Ann NY Acad Sci 1995; 772:105–116.
25. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional
packaging system. J Virol 1998; 72:8463–8471.
26. Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and gene therapy. Front
Biosci 1999; 4:D481–D496.
27. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing
cells by a lentiviral vector. Science 1996; 272:263–267.
28. Parolin C, Sodroski J. A defective HIV-1 vector for gene transfer to human lymphocytes.
J Mol Med 1995; 73:279–288.
29. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy.
Proc Natl Acad Sci USA 1996; 93:11395–11399.
30. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient
in vivo gene delivery. J Virol 1998; 72:9873–9880.
31. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector
achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15:871–875.
32. Amado RG, Mitsuyasu RT, Zack JA. Gene therapy for the treatment of AIDS: animal models
and human clinical experience. Front Biosci 1999; 4:D468–D475.
33. Jamieson BD, Aldrovandi GM, Zack JA. The SCID-hu mouse: an in-vivo model for HIV-
1 pathogenesis and stem cell gene therapy for AIDS. Semin Immunol 1996; 8:215–221.